: iStockAnalyst.com Symbols Feed

Emerging Biotech & Pharma Index: 36 More Cos.

Mon, 24 Nov 2008 05:35:00 GMT

The accompanying table (click to enlarge or download) includes the 36 remaining companies in the ETF Innovators (ETFI) Emerging Bio-Pharma Index with market caps between $150M-$1.5B, which were not included in the previous two articles I wrote about the group – featuring the Top 40 Rated Companies and companies below the $150M market cap cutoff. However, several of the companies included in the remaining group of 36 have been in the news recently due to [More...]

Analyst Comments: Corrections Corp, Alnylam Pharma, Ryland, Eurand Pharma, HCP

Mon, 11 Aug 2008 16:18:00 GMT

Corrections Corporation of America (CXW) holds a significant market share advantage over its peers, with a substantial pipeline of additional capacity scheduled to be added to the portfolio over the next two years. CXW is the clear leader in an industry with a strong outlook, supported by favorable economic and demographic trends. Shares of CXW trade at 21.2x and 17.2x our 2008 and 2009 EPS estimates, respectively. The multiples represent a premium to peer group average multiples of 17.3x and 14.4x consensus 2008 and 2009 EPS estimates, respectively. We note, however, that the consensus estimates for one competitor have yet to be updated after the release of a disappointing full-year outlook and subsequent 17% sell-off in the shares. Additionally, shares of CXW are currently trading at approximately 10.9x and 9.1x our 2008 and 2009 EBITDA estimates, respectively. Only 7% of[More...]

Analyst Comments: China Eastern Airlines, Aladdin, Alnylam Pharmaceuticals, American Oriental, Arch Coal

Tue, 22 Jul 2008 11:55:00 GMT

China Eastern Airlines (CEA) recorded a profit in 2007 and in the first quarter of 2008, mainly due to strong passenger demand in China and the Chinese currency appreciating versus the US dollar. The company is well-positioned to leverage the growth poten[More...]

Investing in microRNA - Beware of Hype, Follow The Money

Wed, 04 Jun 2008 17:19:04 GMT

The momentum in the microRNA (miRNA) field is continuing to build, as evidence that links this group of important genes to multiple diseases, from Alzheimer to diabetes, is constantly mounting. The adoption of miRNAs is further accelerated by the technological advancements in RNA-based therapies. Because miRNAs are not expressed as proteins but as RNA, the most sensible way to target them is using small RNA...[More...]

Analyst Comments: Alpharma, Shanda, Sonic Solutions, HSBC Holdings, Ferrellgas, TriZetto, Compuware, American Axle, Alnylam

Fri, 30 May 2008 22:22:26 GMT

We are maintaining our Sell rating on Alpharma, Inc. (ALO), which is focusing on establishing itself as a specialty pharmaceuticals company after the sale of its generics and active pharmaceutical ingredients business.[More...]

Another RNAi Drugs Deal

Thu, 29 May 2008 20:00:44 GMT

A developer of an emerging class of drugs designed to shut off genes...[More...]

The Metrics of Growth in China Biopharma

Sat, 17 May 2008 21:08:12 GMT

GenePharma, a young and growing private company in the hot siRNA market, was the subject of a profile in ChinaBio® Today that included an exclusive interview with CEO Dr. Peter Zhang; four China-based...[More...]

Rosetta Genomics - Mining Gold Out of Junk

Fri, 11 Apr 2008 06:05:15 GMT

Rosetta Genomics (ROSG) represents one of the most exciting revolutions in biology in recent decades. The company is a pioneer in the field of microRNAs (miRNAs), a group of recently discovered genes that may serve as a novel class of diagnostic markers[More...]

Analyst Comments: Amgen, Jones Lang LaSalle, China Life, Biogen Idec, Apogee, HealthExtras, Alnylam

Tue, 01 Apr 2008 14:36:55 GMT

Amgen, Inc. (AMGN), a global biotechnology company, is focused on the development and commercialization of human therapeutics. The company's key products are Epogen/Aranesp (anemia), Neupogen/Neulasta (neutropenia) and Enbrel (inflammatory disease). Recen[More...]

Shanghai GenePharma Licenses Alnylam siRNA Patents

Sat, 22 Mar 2008 20:41:59 GMT

Shanghai GenePharma Co., Ltd. signed a non-exclusive worldwide license to use the Kreutzer-Limmer siRNA patents belonging...[More...]

Cubist Pharmaceuticals 3rd Quarter Total Net Revenues Up 28%

Thu, 15 Oct 2009 20:46:00 GMT

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced results for the third quarter ended September 30, 2009.
With three quarters of 2009 revenue recorded, Cubist has tightened its full year 2009 guidance for CUBICIN U.S. net revenue to between $520 and $525 Million, which is within the range the company announced in January.
Our strong top and bottom line results have been achieved in an environment that has been tough for many branded pharmaceuticals.

[More...]

Alnylam Announces Allowance in Europe of New Fundamental Patent Broadly Covering RNAi Therapeutics in Oncology

Wed, 09 Sep 2009 11:51:00 GMT

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the European Patent Office (EPO) has issued a notification of intent to grant for a patent in the Kreutzer-Limmer III patent series (EP Application No 02702247.4).
The Kreutzer-Limmer III patent series extends the scope and breadth of Alnylam's fundamental intellectual property estate that comprises numerous issued or granted patents and a large number of pending patent applications that together broadly cover RNAi therapeutics, including small interfering RNAs, or siRNAs, the molecules that mediate RNAi.
"We are pleased with the EPO's decision to grant claims from Kreutzer-Limmer III, an early filed patent in RNAi therapeutics research that described many applications for siRNAs and their use in oncology indications," said Barry Greene, President and Chief Operating Officer of Alnylam Pharmaceuticals.

[More...]

Alnylam and Regulus Receive Notice of Allowance from United States Patent and Trademark Office for New Patent Covering microRNA Therapeutics

Tue, 11 Aug 2009 11:07:00 GMT

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Regulus Therapeutics Inc., a leading microRNA therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has awarded a notice of allowance for the Manoharan patent (application number 11/200,703), which covers several chemical classes of anti-miRs, antisense oligonucleotide inhibitors of microRNAs. This new patent in combination with Regulus’ existing intellectual property estate broadly covers approaches to developing microRNA-based therapeutics.[More...]

Alnylam Pharmaceuticals Reports Second Quarter 2009 Financial Results

Thu, 06 Aug 2009 20:03:00 GMT

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY)[More...]

Alnylam and Tekmira Participate in New Research Collaboration

Thu, 06 Aug 2009 11:08:00 GMT

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Tekmira Pharmaceuticals Corporation (TSX: TKM), announced today that they will jointly participate in a new research collaboration focused on the discovery of novel cationic lipids and lipid nanoparticles for the systemic delivery of RNAi therapeutics.[More...]

Alnylam to Webcast Conference Call Discussing Second Quarter 2009 Financial Results

Thu, 30 Jul 2009 21:37:00 GMT

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the second quarter ending June 30, 2009 on Thursday, August 6, 2009, after the U.S. financial markets close.[More...]

INSERTING and REPLACING Alnylam and Cubist Announce Complete Data from Phase II Study of ALN-RSV01 in Lung Transplant Patients Naturally Infected with Respiratory Syncytial Virus

Mon, 20 Jul 2009 11:47:00 GMT

Insert after 3rd paragraph, 2nd sentence: Bronchiolitis Obliterans Syndrome, or BOS.[More...]

Alnylam and Cubist Announce Complete Data from Phase II Study of ALN-RSV01 in Lung Transplant Patients Naturally Infected with Respiratory Syncytial Virus

Mon, 20 Jul 2009 11:01:00 GMT

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Cubist Pharmaceuticals, Inc. (Nasdaq: CBST), an acute care focused therapeutics company, today reported complete data from their Phase II study of ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection. Data were presented at the BIT Life Science’s 2nd Annual Summit of Antivirals held in Beijing, China from July 18 – 25, 2009. The Phase II study was a randomized, double-blind study of inhaled ALN-RSV01 or placebo in adult lung transplant patients naturally infected with RSV. Clinical evaluations at 90 days confirmed that the primary objective of safety and tolerability was achieved.[More...]

Alnylam Announces Extension of RNAi Therapeutics Collaboration with Novartis

Fri, 17 Jul 2009 10:58:00 GMT

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that Novartis has elected to extend the company’s RNAi therapeutics collaboration for a fifth and final planned year, through October 2010. The landmark alliance was initiated in October 2005 and is focused on the discovery, development, and commercialization of RNAi therapeutics toward a defined number of Novartis-selected disease gene targets.[More...]

Alnylam's Kreutzer-Limmer II Patent Upheld in European Opposition Proceedings

Wed, 15 Jul 2009 11:50:00 GMT

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the European Patent Office (EPO) has upheld its "Kreutzer-Limmer II" '061 (EP 1352061) patent in oral proceedings held before the European Opposition Board.
The '061 patent is the first to be granted in Europe from the Kreutzer-Limmer II patent family, and includes broad claims covering methods of silencing approximately 130 disease genes with small interfering RNAs, or "siRNAs," the molecules that mediate RNAi, which in this case comprise certain stabilizing design features and lengths of up to 49 nucleotides.
The maintenance of all originally granted claims in the Kreutzer-Limmer II '061 patent reinforces the strength of Alnylam's overall intellectual property (IP) estate which is believed by the company to be needed for the development and commercialization of RNAi therapeutics.

[More...]